No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ARVN Arvinas
- 25.670
- -0.780-2.95%
Close Jun 14 16:00 ET
- 25.650
- -0.020-0.08%
Post 18:44 ET
1.76BMarket Cap-4242P/E (TTM)
27.055High25.075Low745.02KVolume26.060Open26.450Pre Close19.04MTurnover1.31%Turnover RatioLossP/E (Static)68.43MShares53.08052wk High2.88P/B1.46BFloat Cap13.57052wk Low--Dividend TTM56.91MShs Float108.465Historical High--Div YieldTTM7.49%Amplitude10.190Historical Low25.553Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Arvinas (NASDAQ:ARVN Investor Three-year Losses Grow to 68% as the Stock Sheds US$99m This Past Week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the long term shareholders of Arvinas, Inc. (NASDAQ:ARVN) have had an unfortunat
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today an
Express News | Arvinas- Due to Hsr Termination & Satisfaction of Closing Conditions of License Agreement, Asset Agreement, Novartis Pharma AG to Pay Co $150.0 Mln
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 c
Form 144 | Arvinas(ARVN.US) Insider Proposes to Sell 1.65 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 20, $Arvinas(ARVN.US)$ Insider Sean Cassidy intends to sell 50,000 shares of its common stock on May 20, with a total market value of approximately $1.65 million. Sean Ca
Comments
Arvinas' high P/S ratio could be worrisome as revenue forecasts are not promising. The anticipated future revenues may not sustain the current positive sentiment. Without significant improvements, these prices may not be deemed reasonable.
Revenues Not Telling The Story For Arvinas, Inc. (NASDAQ:ARVN) After Shares Rise 28% 1
Sean Cassidy expressed confidence in the company's future and the promising clinical development and commercial opportunity for the PROTAC(R) protein degrader pipeline. The company's leadership acknowledged Cassidy's pivotal role in creating Arvinas' strong financial profile.
1
$Arvinas(ARVN.US$ 👀 new hoy
$Arvinas(ARVN.US$ I hope everyone bought that sub 14 dip! This thing has been a beast.
1
Upgrades
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
16
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg